Phaseline

Targets › RIPK1

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2028.

Serine-threonine kinase which is a key regulator of TNF-mediated apoptosis, necroptosis and inflammatory pathways. Exhibits kinase activity-dependent functions that regulate cell death (apoptosis and necroptosis) and kinase-independent scaffold functions regulating inflammatory signaling and cell survival. (UniProt, Q13546)

Open in Phaseline: the race on RIPK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gustave Roussy, Cancer Campus, Grand ParisTOLINAPANT (ASTX660)
RIPK1 inhibitor
RIPK1Phase 1Locally-advanced Rectal CancerJan 2028

Conditions

Locally-advanced Rectal Cancer (1)

Modalities

small molecule (1)

Companies

Gustave Roussy, Cancer Campus, Grand Paris (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.